Effect of Selective Inhibition of the Inducible Cyclooxygenase on Renin Release in Healthy Volunteers

Journal of Investigative Medicine

Volumn 46, Issue 6, 1998, Pages 290-296

  Stichtenoth, Dirk O ^a   Wagner, Bettina ^a   Frölich, Jürgen C ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Inducible cyclooxygenase; Nonsteroidal anti inflammatory drugs; Renin release prostaglandin E2; Selective COX 2 inhibition

Indexed keywords

FUROSEMIDE; INDOMETACIN; ISOENZYME; MELOXICAM; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; RENIN; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; MASS FRAGMENTOGRAPHY; MIDDLE AGED; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; URINE;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; FEMALE; FUROSEMIDE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INDOMETHACIN; ISOENZYMES; MIDDLE AGED; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RADIOIMMUNOASSAY; REFERENCE VALUES; RENIN; THIAZINES; THIAZOLES;

EID: 0032133815     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature [New Biology] 1971;231:232-5.
2. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nature [New Biology] 1971;231:235-7.
3. Whorton AR, Smigel M, Oates JA, Frölich JC. Regional differences in prostaglandin formation by the kidney: prostacyclin is a major prostaglandin of renal cortex. Biochim Biophys Acta 1978;529:176-180.
4. Frölich JC, Stichtenoth DO. NSAID: can renal side effects be avoided? In: Vane JR, Bolting JH, Bolting RM, eds. Improved non- steroid anti-inflammatory drugs: COX-2 enzyme inhibitors. Dordrecht: Kluwer Academic Publishers 1996:203-28.
5. 2. Prostaglandins 1977;14:1095-104.
6. Ito S. Carretero OA, Abe K, Beierwaltes WH, Yoshinaga K. Effect of prostanoids on renin release from rabbit isolated afferent arterioles with and without attached macula densa. Kidney Int 1989;35:1138-44.
7. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-6.
8. Kujubu DA, Fletcher BS, Varnum CR, Lim W, Herschman H. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
9. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 1995;44:1-9.
10. Frölich JC. Prostaglandin endoperoxide synthetase isoenzymes: the clinical relevance of selective inhibition. Ann Rheum Dis 1995;54:942-3.
11. Vane JR. Towards a better aspirin. Nature 1994;367:215-6.
12. Churchill L. Graham AC, Shih CK et al. Selective inhibition of human cyclooxygenase-2 by meloxicam. Inflammopharmacology 1996; 4:125-35.
13. Frölich JC. A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes. Trends Pharmacol Sci 1997;18:30-4.
14. Stichtenoth DO, Wagner B, Frölich JC. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Invest Med 1997;45:44-9.
15. Funk CD, Funk LB, Kennedy ME, Pong AS, Fitzgerald GA. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991;5:2304-12.
16. 2 in healthy men. Prostaglandins 1979;16:623-9.
17. Türck D, Busch U, Heinzel G, Narjes H. Clinical pharmacokinetics of meloxicam. Eur J Rheumatol Inflam 1996;15:23-30.
18. Reynolds JEF, ed. Martindale, the Extra Pharmacopoeia, 30th edition, London: Pharmaceutical press, 1993:19-21.
19. Frölich JC, Wilson TW, Sweetman BJ, Smigel M, Nies AS, Carr K, Watson JT, Oates JA. Urinary prostaglandins. Identification and origin. J Clin Invest 1975;55:763-70.
20. Haber E, Koerner T, Page LB, Kliman B, Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol 1969;29:1349-55.
21. Fauler J, Tsikas D, Mayatepek E, Keppler D, Frölich JC. Impaired degradation of prostaglandins and thromboxane in Zellweger syndrome. Pediatr Res 1994;36:449-55.
22. Frölich JC, Hollifield JW, Dormois JC, Frölich BL, Seyberth HJ, Michelakis AM, Oates JA. Suppression of plasma renin activity by indomethacin in man. Circ Res 1976;39:447-52.
23. Walker LA, Frölich JC. Renal prostaglandins and leukotrienes. Rev Physiol Biochem Pharmacol 1987;107:1-71.
24. 1α determination. Kidney Int. 1981;19:755-9.
25. Brunel P, Hornych A, Guyene TT, Sioufi A, Turri M, Ménard J. Renal and endocrine effects of flosulide, after single and repeated administration to healthy volunteers. Eur J Clin Pharmacol 1995;49:193-201.
26. Vane JR, Botting RM. Overview-mechanisms of action of anti-inflammatory drugs In: Vane JR, Botting JH, Botting RM, eds. Improved non-steroid anti-inflammatory drugs: COX-2 enzyme inhibitors. Dordrecht: Kluwer Academic Publishers 1996:1-27.
27. Harding P, Sigmon DH, Alfie ME, Huang PL, Fishman MC, Beierwaltes WH, Carretero OA. Cyclooxygenase-2 mediates increased renal renin content induced by low sodium diet. Hypertension 1997;29:297-302.
28. Pairet M, Churchill L, Engelhardt G. Differential inhibition of cyclooxygenases 1 and 2 by NSAIDs. In: Bazan N, Bolting J, Vane J, eds. New targets in inflammation. Inhibitors of COX-2 or adhesion molecules. Dordrecht, Boston, London: Kluwer Academic Publishers, William Harvey Press, 1996:23-38.
29. Harris RC, McKanna JA, Akai Y, Jacobson HR, DuBois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-2510.
30. Kömhoff M, Gröne H-J, Klein T, Seyberth HW, Nüsing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney implication for renal function. Am J Physiol 1997;272:F460-8.
31. Ehrich E, Schnitzer T, McIlwain H et al. MK-966, a highly selective COX-2 inhibitor, is effective in the treatment of osteoarthritis in a 6-week pilot study. Poster No 161. 19th ILAR Congress of Rheumatology, Singapore 1997, 47.
32. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-72.
33. Carmichael J, Shankel S. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function. Am J Med 1985;78:992-1000.
34. Bevis PJR, Bird HA, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Brit J Rheumatol 1996;35(1 Suppl):56-60.
35. Degner F. Inhibition of COX-2 and its clinical relevance. Selective COX-2 inhibition, abstracts & posters, 19th ILAR Congress of Rheumatology, Singapore 1997, 31-5.